肿瘤中血管生成信号通路相关药物临床转化研究现状

被引：11

作者：

胡明明

胡瑛

李宝兰

机构：

[1] 北京市结核病胸部肿瘤研究所综合科

来源：

中国肿瘤生物治疗杂志 | 2014年 / 21卷 / 01期

关键词：

肿瘤; 血管生成; 信号转导; 抗肿瘤药物; 临床试验; 转化医学;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

血管生成在肿瘤发生、增殖、侵袭和转移的全程中都扮演着重要角色,以肿瘤血管生成信号通路中的关键分子为靶点开发抗肿瘤药物是目前药物研发的热点。肿瘤相关的血管生成信号通路包括VEGF/VEEFR、血管生成素及其受体、血小板源生长因子及其受体、Delta-like Ligand/Notch、成纤维细胞生长因子及其受体、肝细胞生长因子及其受体、转化生长因子及其受体、内皮素系统等。与肿瘤血管生成通路相关的药物中,贝伐单抗(bevacizumab)、索拉非尼(sorafenib)、舒尼替尼(sunitinib)等药物已经获得FDA的批准,在直肠癌、肾癌、非小细胞肺癌、肝癌、胃肠间质瘤等肿瘤患者中取得了良好效果,数十种尚未被FDA批准的抗血管生成药物也正在全球进行各期临床试验。本文总结肿瘤血管生成信号通路的基础研究及其相关药物临床转化的研究进展。

引用

页码：86 / 94

页数：9

共 33 条

[1]

Targeting angiopoietin-2 signaling in cancer therapy [J].

Eroglu, Zeynep ;

Stein, Cy A. ;

Pal, Sumanta K. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (07) :813-825

[2]

Gene silencing of c-Met leads to brain metastasis inhibitory effects [J].

Lee, Se Jeong ;

Seol, Ho Jun ;

Lee, Hye Won ;

Kang, Won Young ;

Kang, Bong Gu ;

Jin, Juyoun ;

Jo, Mi-Young ;

Jin, Younggeon ;

Lee, Jung-Il ;

Joo, Kyeung Min ;

Nam, Do-Hyun .

CLINICAL & EXPERIMENTAL METASTASIS, 2013, 30 (07) :845-854

[3]

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors [J].

Feldman, Darren R. ;

Einhorn, Lawrence H. ;

Quinn, David I. ;

Loriot, Yohann ;

Joffe, Johnathan K. ;

Vaughn, David J. ;

Flechon, Aude ;

Hajdenberg, Julio ;

Halim, Abdel-Baset ;

Zahir, Hamim ;

Motzer, Robert J. .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) :1016-1022

[4]

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14) [J].

Cognetti, F. ;

Bagnato, A. ;

Colombo, N. ;

Savarese, A. ;

Scambia, G. ;

Sehouli, J. ;

Wimberger, P. ;

Sorio, R. ;

Harter, P. ;

Mari, E. ;

McIntosh, S. ;

Nathan, F. ;

Pemberton, K. ;

Baumann, K. .

GYNECOLOGIC ONCOLOGY, 2013, 130 (01) :31-37

[5]

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study [J].

Schilder, R. J. ;

Sill, M. W. ;

Lankes, H. A. ;

Gold, M. A. ;

Mannel, R. S. ;

Modesitt, S. C. ;

Hanjani, P. ;

Bonebrake, A. J. ;

Sood, A. K. ;

Godwin, A. K. ;

Hu, W. ;

Alpaugh, R. K. .

GYNECOLOGIC ONCOLOGY, 2013, 129 (01) :86-91

[6]

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.[J].David I Quinn;Catherine M Tangen;Maha Hussain;Primo N Lara;Amir Goldkorn;Carol M Moinpour;Mark G Garzotto;Philip C Mack;Michael A Carducci;J Paul Monk;Przemyslaw W Twardowski;Peter J Van Veldhuizen;Neeraj Agarwal;Celestia S Higano;Nicholas J Vogelzang;Ian M Thompson.Lancet Oncology.2013,

[7]

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Tomczak, Piotr ;

Hutson, Thomas E. ;

Michaelson, M. Dror ;

Negrier, Sylvie ;

Oudard, Stephane ;

Gore, Martin E. ;

Tarazi, Jamal ;

Hariharan, Subramanian ;

Chen, Connie ;

Rosbrook, Brad ;

Kim, Sinil ;

Rini, Brian I. .

LANCET ONCOLOGY, 2013, 14 (06) :552-562

[8]

Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients [J].

Tahover, Esther ;

Uziely, Beatrice ;

Salah, Azzam ;

Temper, Mark ;

Peretz, Tamar ;

Hubert, Ayala .

MEDICAL ONCOLOGY, 2013, 30 (01)

[9]

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study [J].

Santoro, Armando ;

Rimassa, Lorenza ;

Borbath, Ivan ;

Daniele, Bruno ;

Salvagni, Stefania ;

Van Laethem, Jean Luc ;

Van Vlierberghe, Hans ;

Trojan, Joerg ;

Kolligs, Frank T. ;

Weiss, Alan ;

Miles, Steven ;

Gasbarrini, Antonio ;

Lencioni, Monica ;

Cicalese, Luca ;

Sherman, Morris ;

Gridelli, Cesare ;

Buggisch, Peter ;

Gerken, Guido ;

Schmid, Roland M. ;

Boni, Corrado ;

Personeni, Nicola ;

Hassoun, Ziad ;

Abbadessa, Giovanni ;

Schwartz, Brian ;

Von Roemeling, Reinhard ;

Lamar, Maria E. ;

Chen, Yinpu ;

Porta, Camillo .

LANCET ONCOLOGY, 2013, 14 (01) :55-63

[10]

Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells [J].

Byron, Sara A. ;

Loch, David C. ;

Pollock, Pamela M. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (09) :1517-1526

← 1 2 3 4 →